@article{2da6f3887791431ba6caad945feb8dad,
title = "Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate",
abstract = "The addition of clopidogrel to aspirin treatment reduces ischemic events in a wide range of patients with cardiovascular disease. However, recurrent ischemic event occurrence during dual antiplatelet therapy, including stent thrombosis, remains a major concern. Platelet function measurements during clopidogrel treatment demonstrated a variable and overall modest level of P2Y12 inhibition. High on-treatment platelet reactivity to adenosine diphosphate (ADP) was observed in selected patients. Multiple studies have now demonstrated a clear association between high on-treatment platelet reactivity to ADP measured by multiple methods and adverse clinical event occurrence. However, the routine measurement of platelet reactivity has not been widely implemented and recommended in the guidelines. Reasons for the latter include: 1) a lack of consensus on the optimal method to quantify high on-treatment platelet reactivity and the cutoff value associated with clinical risk; and 2) limited data to support that alteration of therapy based on platelet function measurements actually improves outcomes. This review provides a consensus opinion on the definition of high on-treatment platelet reactivity to ADP based on various methods reported in the literature and proposes how this measurement may be used in the future care of patients.",
keywords = "adenosine diphosphate, percutaneous coronary intervention, platelet reactivity, thrombotic events",
author = "Laurent Bonello and Tantry, {Udaya S.} and Rossella Marcucci and Ruediger Blindt and Angiolillo, {Dominick J.} and Richard Becker and Bhatt, {Deepak L.} and Marco Cattaneo and Collet, {Jean Philippe} and Thomas Cuisset and Christian Gachet and Gilles Montalescot and Jennings, {Lisa K.} and Dean Kereiakes and Dirk Sibbing and Dietmar Trenk and {Van Werkum}, {Jochem W.} and Franck Paganelli and Price, {Matthew J.} and Ron Waksman and Gurbel, {Paul A.}",
note = "Funding Information: Dr. Marcucci has received an honorary fee as a consultant for Ely-Lilly. Dr. Angiolillo has received lecture fees from Bristol-Myers Squibb, Sanofi-Aventis, Eli Lilly and Company, and Daiichi Sankyo, Inc.; honoraria for serving on the advisory boards of Bristol-Myers Squibb, Sanofi-Aventis, Eli Lilly and Company, Daiichi Sankyo Inc., AstraZeneca, The Medicines Company, Portola Pharmaceuticals, Novartis, Medicure, Accumetrics, Arena Pharmaceuticals, Merck, and Evolva Pharmaceuticals; and research grants from GlaxoSmithKline , Otsuka , Boston Scientific , Accumetrics , Eli Lilly and Company , Daiichi Sankyo Inc. , The Medicines Company , AstraZeneca , Eisai , Portola Pharmaceutical , Schering-Plough , and Johnson & Johnson . Dr. Becker has received research grants from AstraZeneca , Bayer , Bristol-Myers Squibb , Johnson & Johnson , The Medicines Company , Schering-Plough , and Merck and has served on the scientific advisory boards of Eli Lilly and Daiichi Sankyo Inc.; his institution performs clinical research supported by AstraZeneca. Dr. Bhatt has received research grants from AstraZeneca , Bristol-Myers Squibb , Eisai , Ethicon , Heartscape , Sanofi-Aventis , and The Medicines Company . Dr. Cattaneo has received lecture honoraria from Eli Lilly/Daiichi Sankyo Inc., AstraZeneca, and The Medicines Company. Dr. Collet has received research grants from Bristol-Myers Squibb , Sanofi-Aventis , Eli Lilly , F{\'e}d{\'e}ration Fran{\c c}aise de Cardiologie , Soci{\'e}t{\'e} Fran{\c c}aise de Cardiologie , Fondation de France , INSERM , Medtronic , Guerbet Medical , Cordis , and Stago ; consultant fees from Sanofi-Aventis, Eli Lilly, and Bristol-Myers Squibb; and lecture fees from Bristol-Myers Squibb, Sanofi-Aventis, and Eli Lilly. Dr. Gachet has received research grants from Stago , Sanofi-Aventis , Bristol-Myers Squibb , and Servier and honoraria from Sanofi-Aventis, Bristol-Myers Squibb, Servier, and Eli Lilly, and has also served on the scientific advisory boards of Sanofi-Aventis and Bristol-Myers Squibb. Dr. Montalescot has received research grants from Abbott Vascular , Bristol-Myers Squibb , Boston Scientific , Cordis , F{\'e}d{\'e}ration Fran{\c c}aise de Cardiologie , Soci{\'e}t{\'e} Fran{\c c}aise de Cardiologie, Fondation de France , Guerbet Medical , INSERM , Medtronic , Sanofi-Aventis , Eli Lilly , Stago , Centocor , ITC Edison , and Pfizer ; consulting fees from AstraZeneca, Eisai, Menarini, Novartis, Pfizer, Portola, Schering-Plough, Sanofi-Aventis, Eli Lilly, Bristol-Myers Squibb, The Medicines Company, Daiichi Sankyo Inc., Bayer, and Boehringer Ingelheim; and lecture fees from Abbott Vascular, Cordis, Menarini, Pfizer, Schering-Plough, Sanofi-Aventis, Eli Lilly, Bristol-Myers Squibb, Merck Sharpe and Dohme, GlaxoSmithKline, Accumetrics, AstraZeneca, and Daiichi Sankyo Inc. Dr. Jennings has served as a consultant for AstraZeneca, Daiichi Sankyo Inc., Schering-Plough/Merck, Sanofi-Aventis/Bristol-Myers Squibb, and Portola; has received grant support from AstraZeneca and Schering-Plough/Merck ; and has served on the Speakers' Bureaus of Sanofi-Aventis and Bristol-Myers Squibb. Dr. Kereiakes has received modest grant and/or research support from Abbott Vascular , Amylin Pharmaceuticals , and Boston Scientific ; has received modest consulting fees from Eli Lilly, Boston Scientific, Abbott Vascular, Medpace, and REVA Medical Inc.; and has served on the Speakers' Bureau for Eli Lilly. Dr. Sibbing has received speaker fees from Dynabyte and The Medicines Company, as well as fees for advisory board activities from Eli Lilly. Dr. Trenk has received grants/research support from and served on the Speakers' Bureaus of Eli Lilly and Daiichi Sankyo Inc . Dr. Van Werkum has received speaker fees from Accumetrics and Siemens and has been a consultant for and served on the advisory board of The Medicines Company. Dr. Paganelli has received lecture fees from Sanofi-Aventis. Dr. Price has received research grants/support from Bristol-Myers Squibb/Sanofi-Aventis and Accumetrics and consulting and/or speaker fees from AstraZeneca, Daiichi Sankyo Inc./Eli Lilly, Bristol-Myers Squibb/Sanofi-Aventis, The Medicines Company, and Accumetrics. Dr. Waksman has received consulting and speaker fees from Biotronik, Medtronic, and Boston Scientific and research grants from Eli Lilly , Sanofi-Aventis/Bristol-Myers Squibb , Biotronik , Boston Scientific , The Medicines Company , GlaxoSmithKline , and Schering-Plough . Dr. Gurbel has received research grants from Schering-Plough , Millenium , AstraZeneca , National Institutes of Health , Hemoscope , Medtronic , Eli Lilly/Daiichi Sankyo Inc. , Sanofi-Aventis , Porotola , Bristol-Myers Squibb , Boston Scientific , Bayer , and Pozen ; and honoraria from Schering-Plough, Portola, AstraZeneca, Bayer, and Medtronic. All other authors have reported that they have no relationships to disclose.",
year = "2010",
month = sep,
day = "14",
doi = "10.1016/j.jacc.2010.04.047",
language = "English (US)",
volume = "56",
pages = "919--933",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "12",
}